Lucentis biosimilar could offer safer option than compounded Avastin, says Pfenex
A biosimilar of Roche’s Lucentis could offer a safer universal treatment for wet AMD than off-label use of Avastin - as recommended by the WHO - according to Pfenex.
Archives for May 18, 2015
Bioquell mulls sale citing investor interest in pharma and worries resistance worries as growth opportunities
Bioquell has launched a strategic review of its contamination control technology business which could result in a sale of the company.
Cancer-hunting shark proteins are the future of drug conjugation, says Almac
Almac is coupling tiny shark proteins to a cancer-killing warhead to develop an oncology drug, saying their small size makes for easy conjugation.
AstraZeneca eyes up flexible single-use tech at $285m Swedish biologics plant
Single-use technologies will ensure flexibility at a $285m (€255m) biologics plant being constructed in Sweden, says AstraZeneca.